BRIEF-Oncolytics says ovarian cancer drug shows benefit in mid-stage study
March 21 (Reuters) - Oncolytics Biotech
* Update for randomized phase ii clinical trial reolysin in combination with paclitaxel in patients with ovarian cancer
* Performed an intent-to-treat analysis of tumour response, which showed statistically significantly higher full response rates Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)
© Thomson Reuters 2017 All rights reserved.